首页|期刊导航|Hepatobiliary & Pancreatic Diseases International|Clinicopathological features and prognosis of dual-phenotype hepatocellular carcinoma after curative hepatectomy:A propensity score matching analysis

Clinicopathological features and prognosis of dual-phenotype hepatocellular carcinoma after curative hepatectomy:A propensity score matching analysisOA

中文摘要

Background:Dual-phenotype hepatocellular carcinoma(DPHCC)is a recently defined subtype of hepato-cellular carcinoma(HCC)characterized by the simultaneous hepatocellular and biliary epithelial marker expression.This study aimed to elucidate the clinicopathological features of DPHCC following curative liver resection and its relationship with prognosis.Methods:We analyzed 1493 patients with HCC who underwent curative liver resection at the Peking Union Medical College Hospital from January 2013 to December 2023.All patients were divided into two groups according to immunohistochemical marker expression,with 487 and 1006 cases in the DPHCC and non-DPHCC groups,respectively.Propensity score matching was performed to reduce the deviation caused by baseline characteristics.Results:After 1:2 matching(DPHCC/non-DPHCC group=453/771),patients were comparable regard-ing all baseline characteristics.Compared to patients with non-DPHCC,those with DPHCC were signifi-cantly associated with poorer differentiation,microvascular invasion,satellite nodules,and bile duct tu-mor thrombus(P<0.05).Patients with DPHCC also exhibited significantly worse recurrence-free survival(P=0.009)and overall survival(P=0.021).Furthermore,multivariate analysis revealed that DPHCC was an independent risk factor for recurrence-free survival(HR=1.28,95%CI:1.05-1.52,P=0.019)and over-all survival(HR=1.33,95%CI:1.15-1.51,P=0.023).Conclusions:DPHCC,a newly proposed subtype of HCC,is associated with poorer clinicopathological features and adverse prognosis,providing important clinical guidance.

Tai-Feng Zhu;Zi-Yue Huang;Xiao-Kun Chen;Cheng-Pei Zhu;Shun-Da Du;Xin-Ting Sang;Yong-Chang Zheng;Hai-Tao Zhao

Department of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing100010,ChinaDepartment of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing100010,ChinaDepartment of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing100010,ChinaDepartment of General Surgery Center,Beijing Youan Hospital,Clinical Center for Liver Cancer,Capital Medical University,Beijing 100000,ChinaDepartment of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing100010,ChinaDepartment of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing100010,ChinaDepartment of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing100010,ChinaDepartment of Liver Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing100010,China

医药卫生

Dual-phenotype hepatocellular carcinomaPrognosisRecurrence-free survivalOverall survivalPropensity score matching

《Hepatobiliary & Pancreatic Diseases International》 2026 (4)

P.414-421,8

supported by grants from the Beijing Natural Science Foundation(L248022)National High Level Hospital Clin-ical Research Funding(2025-PUMCH-C-015,2025-PUMCH-D-001)CAMS Innovation Fund for Medical Sciences(CIFMS)(2021-I2M-1-061,2021-I2M-1-003)Peking Union Medical College Hospital Out-standing Young Talent Development Program(UBJ10528).

10.1016/j.hbpd.2026.03.002

评论